Earthpharm Technologies

The Science

A multi-target intervention
against the oxidative cascade driving
diabetic peripheral neuropathy.

EP-001 engages eight upstream targets in the neuropathy cascade — validated first in silico, then confirmed in vitro on human neurons under hyperglycemic stress.

Where existing drugs stop

Diabetic neuropathy sits downstream of six interacting pathways at least. Every first-line drug treats one of them.

The biology needs a set of validated interventions delivered together, hitting the same cell at the same time. Difficult to build inside a single synthetic molecule. What a standardised botanical matrix delivers by construction.

In silico · Multi-target coverage

EP-001 was validated computationally against eight upstream targets across the neuropathy cascade.

Direct diabetic neuropathy literature
SIRT1 Mitochondrial Neuronal SIRT1 overexpression prevents and reverses experimental diabetic neuropathy. Open literature Chandrasekaran et al., Brain, 2019
RAGE Immune RAGE-knockout mice are largely protected from diabetic loss of pain perception. Open literature Bierhaus et al., J Clin Invest, 2004
MAO-B Oxidative MAOB is upregulated in sciatic nerve of DPN patients; selective inhibition alleviates pathology. Open literature Song et al., Acta Pharmacol Sin, 2026
TLR4 Immune TLR4 signalling drives inflammatory injury in dorsal root ganglion neurons in diabetic models. Open literature Chen et al., Sci Rep, 2017
Aldose Reductase Metabolic Canonical systematic review of aldose reductase inhibitor trials in diabetic polyneuropathy. Open literature Chalk et al., Cochrane Database Syst Rev, 2007
AChE Signal Acetylcholinesterase deficiency contributes to synaptic dysfunction in diabetic peripheral neuropathy. Open literature Garcia et al., Am J Physiol Endocrinol Metab, 2012
Glycemic control — upstream of neuropathic progression
α-Glucosidase Glycemic Systematic review of α-glucosidase inhibitors in delaying type 2 diabetes and its complications. Open literature Moelands et al., Cochrane Database Syst Rev, 2018
α-Amylase Glycemic Dual α-glucosidase/α-amylase inhibition as a validated strategy for postprandial glucose control. Open literature Lam et al., Nat Prod Bioprospect, 2024

Citations link to open-domain literature establishing each target’s role. Earthpharm’s binding profile and per-target mechanistic detail are reserved for partner conversations under NDA.

In vitro · Signal

Tested on human neurons under hyperglycemic oxidative stress — the actual disease event.

94 %

Neuronal survival

400 %

Mitochondrial restoration

~0

Apoptosis

Complete dataset available under scientific NDA.

Delivery

Delivered orally through a proprietary sub-100nm nanocarrier system.

Sub-100nm particles cross membrane barriers that stop conventional oral formulations. Encapsulation shields the actives from first-pass metabolism. Peripheral nerve tissue gets the delivered dose, not what’s left of it.

The nanocarrier is proprietary and part of the Earthpharm IP estate under counsel.

Where the programme is now

Preclinical. In-vivo model entering setup this quarter. IND-enabling toxicology follows.

Regulatory strategy runs on two parallel tracks — CDSCO Phytopharmaceutical for India, FDA 505(b)(2) for out-licensing. The datasets do double duty across both.

Scientific collaboration Meet the team